257 related articles for article (PubMed ID: 20921210)
21. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment.
Müller S; Kohanbash G; Liu SJ; Alvarado B; Carrera D; Bhaduri A; Watchmaker PB; Yagnik G; Di Lullo E; Malatesta M; Amankulor NM; Kriegstein AR; Lim DA; Aghi M; Okada H; Diaz A
Genome Biol; 2017 Dec; 18(1):234. PubMed ID: 29262845
[TBL] [Abstract][Full Text] [Related]
22. Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas.
Sun X; Liu X; Xia M; Shao Y; Zhang XD
J Transl Med; 2019 May; 17(1):159. PubMed ID: 31097021
[TBL] [Abstract][Full Text] [Related]
23. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
24. Immunogene therapy as a treatment for malignant brain tumors in young mice.
Glick RP; Lichtor T; Lin H; Tarlock K; Cohen EP
J Neurosurg; 2006 Jul; 105(1 Suppl):65-70. PubMed ID: 16871873
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell-based immunotherapy for malignant gliomas.
Akasaki Y; Black KL; Yu JS
Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
[TBL] [Abstract][Full Text] [Related]
26. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ
Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860
[TBL] [Abstract][Full Text] [Related]
27. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
Wei J; Nduom EK; Kong LY; Hashimoto Y; Xu S; Gabrusiewicz K; Ling X; Huang N; Qiao W; Zhou S; Ivan C; Fuller GN; Gilbert MR; Overwijk W; Calin GA; Heimberger AB
Neuro Oncol; 2016 May; 18(5):639-48. PubMed ID: 26658052
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
[TBL] [Abstract][Full Text] [Related]
29. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
Parker JN; Gillespie GY; Love CE; Randall S; Whitley RJ; Markert JM
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2208-13. PubMed ID: 10681459
[TBL] [Abstract][Full Text] [Related]
30. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.
Yang L; Ng KY; Lillehei KO
Cancer Control; 2003; 10(2):138-47. PubMed ID: 12712008
[TBL] [Abstract][Full Text] [Related]
31. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of local immunoresistance in glioma.
Albesiano E; Han JE; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
[TBL] [Abstract][Full Text] [Related]
33. Single vs. combination immunotherapeutic strategies for glioma.
Chandran M; Candolfi M; Shah D; Mineharu Y; Yadav VN; Koschmann C; Asad AS; Lowenstein PR; Castro MG
Expert Opin Biol Ther; 2017 May; 17(5):543-554. PubMed ID: 28286975
[TBL] [Abstract][Full Text] [Related]
34. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.
Chae M; Peterson TE; Balgeman A; Chen S; Zhang L; Renner DN; Johnson AJ; Parney IF
Neuro Oncol; 2015 Jul; 17(7):978-91. PubMed ID: 25537019
[TBL] [Abstract][Full Text] [Related]
35. Immune microenvironment of gliomas.
Gieryng A; Pszczolkowska D; Walentynowicz KA; Rajan WD; Kaminska B
Lab Invest; 2017 May; 97(5):498-518. PubMed ID: 28287634
[TBL] [Abstract][Full Text] [Related]
36. Tumour immune landscape of paediatric high-grade gliomas.
Ross JL; Velazquez Vega J; Plant A; MacDonald TJ; Becher OJ; Hambardzumyan D
Brain; 2021 Oct; 144(9):2594-2609. PubMed ID: 33856022
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
38. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.
Thaci B; Ahmed AU; Ulasov IV; Wainwright DA; Nigam P; Auffinger B; Tobias AL; Han Y; Zhang L; Moon KS; Lesniak MS
Cancer Gene Ther; 2014 Jan; 21(1):38-44. PubMed ID: 24434573
[TBL] [Abstract][Full Text] [Related]
39. Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models.
Sabbagh A; Beccaria K; Ling X; Marisetty A; Ott M; Caruso H; Barton E; Kong LY; Fang D; Latha K; Zhang DY; Wei J; DeGroot J; Curran MA; Rao G; Hu J; Desseaux C; Bouchoux G; Canney M; Carpentier A; Heimberger AB
Clin Cancer Res; 2021 Aug; 27(15):4325-4337. PubMed ID: 34031054
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development.
Garcia-Fabiani MB; Ventosa M; Comba A; Candolfi M; Nicola Candia AJ; Alghamri MS; Kadiyala P; Carney S; Faisal SM; Schwendeman A; Moon JJ; Scheetz L; Lahann J; Mauser A; Lowenstein PR; Castro MG
Expert Opin Investig Drugs; 2020 Jul; 29(7):659-684. PubMed ID: 32400216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
